Anxiety and Depression in Patients with Hematologic Cancers
Official title: An Observational Prospective Cohort Study of Anxiety and Depression in Patients With Hematologic Malignancies
Run by The First Affiliated Hospital of Xiamen University · NCT07883070 · Data updated 2026-11-12
This study tests whether anxiety and depression levels before and after treatment are linked to treatment outcomes in people newly diagnosed with lymphoma, multiple myeloma, or leukemia.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Locations | 1 site (Xiamen, Fujian) |
| Status | Recruiting |
| Started | October 20, 2026 |
| Main results expected | December 1, 2030 |
| Study ends | December 1, 2030 |
| Registry record updated | November 5, 2026 |
| Trial ID | NCT07883070 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with hematologic malignancies (lymphoma, multiple myeloma, or leukemia) who are starting standard therapy and can complete regular mood assessments.
✕Probably not a fit
Patients who do not experience mood changes or who have short follow-up may derive little direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, prospective observational study enrolling about 100 patients. Anxiety and depression will be measured with the Hospital Anxiety and Depression Scale before treatment and at 3, 6, and 12 months after treatment starts. All patients receive standard cancer therapy, and they will be followed for at least 24 months to explore how mood symptoms relate to treatment failure, progression-free survival, overall survival, response, and tolerability.
Why it matters
Potential benefit: If associations are found, clinicians may better understand how mood symptoms relate to treatment outcomes and tailor supportive care accordingly.
How similar studies have gone: Previous research in cancer populations has shown links between mood symptoms and treatment outcomes, but data in hematologic cancers are less extensive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with hematologic malignancies who visit the Department of Hematology at the First Affiliated Hospital of Xiamen University from August 2026 onward, including lymphoma, multiple myeloma, and leukemia. 2. Patients who are able to understand and voluntarily participate in anxiety and depression status assessments. Exclusion Criteria: 1\. Patients with any other conditions considered by the investigator to be inappropriate for participation in this study.
Where it's running
-
the First Affilaited Hospital of Xiamen University
Xiamen, Fujian, China Recruiting
Study contacts
- Principal investigator: Zhijuan Lin, Dr — The First Affiliated Hospital of Xiamen University
- Study coordinator: Zhijuan Lin, Dr
- Email: zjuan_lin@126.com
- Phone: 15960283462
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HLA mismatched stem cell transplantation for hematologic diseases
This study is testing a new stem cell transplant approach for patients with blood cancers who can't find matching donors to see if it can improve their chances of recovery.
-
68Ga-XHER2 PET/CT imaging to see HER2 in solid tumors
A noninvasive PET/CT imaging test using 68Ga-XHER2 is being tried to see if it reflects HER2 levels in solid tumors.
-
68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery
This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.
-
VCC combination in relapsed or refractory AML
A group of adults with relapsed or refractory AML will receive a three-drug combo (venetoclax, chidamide, and chiglitazar sodium) to see if it helps control the leukemia.
-
Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL
This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.